Evidence overview
Quercetin
Quercetin is a plant flavonoid studied most heavily for cardiometabolic outcomes (blood pressure, lipids, blood glucose), inflammatory biomarkers, allergic responses (where it shows mast-cell-stabilizing effects), and exercise-related applications. The evidence base has accumulated multiple umbrella reviews and meta-analyses over the past five years. Oral bioavailability is the defining practical question for the supplement, with absorption-enhanced formulations differing substantially in systemic availability.
Most studied for
Immune support
PubMed coverage
3,461 studies
Safety profile
Limited
Mechanism class
Plant-derived flavonoid in the flavonol subclass, found naturally in onions, apples, capers, berries, and...
Study coverage
Study coverage by goal
PubMed counts for Quercetin grouped by the goal each study targets.
Evidence
What the evidence covers
What's been studied. Conclusions live in your personalized report.
Quercetin is a plant-derived flavonoid in the flavonol subclass, found naturally in onions, apples, capers, berries, and tea. The supplement literature spans cardiometabolic outcomes (blood pressure, lipid profiles, blood glucose, vascular function), inflammatory and antioxidant biomarkers, allergic and histamine-related conditions (where quercetin shows mast-cell-stabilizing effects), exercise-related applications including endurance and immune function, and broader anti-inflammatory uses. The compound modulates multiple cellular pathways including NF-kB signaling and mast cell activation, which is the conceptual basis for its unusually wide indication base.
The outcome dimensions covered most heavily are cardiometabolic markers (the most-studied area, anchored by recent umbrella reviews on blood pressure, lipid profiles, and glucose), inflammatory and antioxidant biomarkers in adults with metabolic syndrome and related conditions, allergic responses including allergic rhinitis (the mast-cell-stabilizing mechanism), exercise immunology in athletes, and broader anti-inflammatory uses. Newer research streams cover quercetin in upper respiratory infections (especially post-2020), cognitive function, and dermatologic applications.
Demographically, the cardiometabolic literature concentrates on adults with metabolic syndrome, prehypertension, or established cardiovascular risk factors. Bioavailability is the central practical issue: standard quercetin (aglycone form) has poor absorption (typically below 5% in unenhanced products), which has driven development of absorption-enhanced formulations including phytosome (Quercefit), EMIQ (enzymatically modified isoquercitrin), and lecithin-based delivery systems. Bioavailability differences between products are substantial (commonly reported in the 10-20x range), which means trial results depend heavily on the formulation used.
Safety
Safety summary
Common adverse events, drug interactions, and special populations.
Quercetin is generally well-tolerated at typical supplemental doses (500-1,000 mg/day) and has GRAS status from the FDA. The most-common adverse effects are gastrointestinal upset, headache, and occasional tingling in the extremities at higher doses. No tolerable upper limit has been established but very high chronic doses (above 1 g/day for extended periods) lack long-term safety data. Drug interactions include inhibition of several CYP enzymes including CYP3A4, which means quercetin may affect blood levels of medications metabolized by these enzymes (statins, calcium channel blockers, and many others); the clinical significance is dose-dependent and product-dependent. Quercetin also affects fluoroquinolone antibiotic absorption (separate dosing recommended). People on cyclosporine, certain chemotherapy agents, or any narrow-therapeutic-index medication should consult a clinician.
This summary is informational and not medical advice. Consult a clinician before starting or changing any supplement, especially if you take prescription medications.
Foundations
Foundation of the evidence base
A few studies the field anchors on. Not the full picture, just the starting points.
Umbrella review (the highest level of evidence synthesis) covering quercetin's cardiometabolic indication base - the supplement's most-studied research area and the one anchoring most field-level discussion.
View on PubMedComprehensive meta-analysis on quercetin across the three major cardiometabolic markers simultaneously (blood pressure, lipid profiles, glucose) - the broader-context reference for the supplement's cardiometabolic claims.
View on PubMedSynthesis of evidence on quercetin specifically in metabolic syndrome populations - the most-studied target population for the supplement's primary indication area.
View on PubMed
Limitations
What this page doesn't answer
Where the public summary stops and the personalized report begins.
This page summarizes the quercetin literature at a general level. It does not address which formulation (standard aglycone, phytosome/Quercefit, EMIQ, or lecithin-enhanced) is right for your specific goal, what equivalent dose to use given the chosen formulation, whether your medication list flags any CYP-related interaction concerns, or which research stream (cardiometabolic, allergic, exercise-related) is most relevant to your case. Formulation bioavailability is the single most-consequential variable in quercetin trials.
Personalized to you
Get a personalized Quercetin report
Your free first report adds the things this page doesn't: per-goal evidence breakdown, demographic-specific findings, full citation list, and a safety section tailored to your profile, opening with a short plain-language summary so you can orient in seconds before drilling in.
Free first report. No credit card. Cancel anytime.
Get notified when new evidence appears
We'll email you when the literature on Quercetin materially updates. No account required.